The American Association for Cancer Research (AACR) Annual Meeting is being held digitally this year from the 10-15 April and 17-21 May. Oxford cancer researchers will be involved in live-streamed presentations, panel discussions and poster sessions.
The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world.
Register to attend this event here or check out what Oxford’s researchers will be talking about below.
Drug Development & Therapies
- Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation (poster) – Mark Middleton, Department of Oncology, 10 April
- Stratification of radiotherapy and fluoropyrimidine-based chemotherapy from multi-omic profiling in rectal cancer biopsies (poster) – Enric Domingo et al., Department of Oncology, 10 April
- Predicting clinical pharmacokinetics and toxicity of current and emerging oncology therapeutics by normothermic perfusion of isolated human-sized organs (poster) – Tamsyn Clark, Institute for Biomedical Engineering, 10 April
- Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumours (poster) – Eileen Parkes, Department of Oncology, 10 April
- What Is the Role for Oncolytic Viruses in Cancer Treatment? (live session)– Len Seymour, Department of Oncology, 13 April
- Deubiquitylating Enzymes (DUBs) as Targets for Cancer Therapy Panel– Benedikt Kessler, NDM, 14 April
- Deciphering the role of TPC2 in cancer immunology: from bench to bedside (poster) – Abeer Alharbi, Department of Pharmacology, 10 April
- Mechanistic insights into the hypoxia-induced DNA damage response (live session) – Ester Hammond, Department of Oncology, 9 April
- From bench to bedside: Using ProTide chemistry to transform 3’-deoxyadenosine into the novel anti-cancer agent Nuc-7738 (poster) – Hagen Schwenzer, Department of Oncology, 10 April
- Tumour Hypoxia and Genetic Instability Panel – Ester Hammond, Department of Oncology, 15 April
- PRMT5 inhibition reduces viability and stemness of pediatric high grade glioma (poster) – Elizabeth Brown, NDORMS, 15 April
- Long non-coding RNA NORAD interaction with miR-346 impacts DNA damage response and anti-tumor immunity in prostate cancer (poster) – Claire Fletcher, Department of Pharmacology, 15 April
- Functional annotations of membrane transport genes using genetic perturbation screens (poster)– Heba Sailem, Big Data Institute, 10 April